

Technology Advisory Committee D Interests Register

Topic: Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

Publication Date: 26 March 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Matthew Bradley	Committee Member	Direct – Financial	Prior to the meeting, Dr Bradley declared that he is an employee of GlaxoSmithKline, the manufacturer of lamotrigine (an identified competitor).	15/12/2023 07/02/2024	It was agreed that Dr Bradley's declaration would prevent him from participating in discussions on this appraisal.
Will Sullivan	Committee Member	Direct - Financial	<ul style="list-style-type: none"> In a role Will has since left, Will's previous employer was paid for him and a wider team to provide consultancy work to Jazz Pharmaceuticals for a different product and different indication to those in this appraisal, in the last 12 months. In a role Will has since left, Will's previous employer was paid for him and a wider team to provide consultancy work to GlaxoSmithKline for different products and different 	18/12/2023 09/02/2024 15/01/2025	It was agreed that Will's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>indications to those in this appraisal, in the last 12 months</p> <ul style="list-style-type: none"> In his current role, Will is part of a team providing consultancy work to Eisai for a different product and different indication to those in this appraisal 		
Professor David Meads	Committee Member	Non-Financial Professional	Professor Meads' employer, the University of Leeds, has received funding from Sanofi and Janssen for research in an unrelated area.	<p>21/12/2023</p> <p>15/01/2025</p>	It was agreed that Professor Meads' declaration would not prevent him from participating in discussions on this appraisal.
Philip Mallender	Committee Member	Non-Financial Professional	Philip works for Medtronic who have a Deep Brain Stimulation technology for epilepsy which stimulates the Anterior Nucleus of Thalamus (ANT). Vagus nerve stimulation, which is a non-pharmacological therapy, is listed as a potential comparator in the scope. The key comparators in this appraisal are pharmacological therapies.	<p>4/1/2024</p> <p>13/02/2024</p> <p>15/01/2025</p>	It was agreed that Philip's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Pooja Takhar	Patient expert	Direct – Financial	Pooja's nominating organisation, Tuberous Sclerosis Association, has received funding from the comparator company Jazz Pharma Ltd.	11/01/2024 15/01/2025	It was agreed that Pooja's declaration would not prevent her from providing expert advice to the committee.
Dr Rhys Thomas	Clinical expert	Direct - Financial	<ul style="list-style-type: none"> Dr Thomas has received honoraria for speaking and advisory boards in the last 12 months: Angelini, Eisai, Jazz Pharmaceuticals, LivaNova, Takeda, UCB Pharma, UNEEG Dr Thomas has received meeting support in last 12 months from Angelini and UCB Pharma Dr Thomas has received unrestricted education grants: Arvelle/Angelini, UNEEG Dr Thomas has just started a joint working partnership with UCB. His hospital, the Royal Victoria Infirmary (NUTH), has received £50,000 for a one-year project to fund genomic practitioners to take consent for genetic testing. The project will be testing people with early onset seizures including 	30/06/2023 11/01/2024 6/3/2024	It was agreed that Dr Thomas' declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			people with LGS. Dr Thomas takes no fees from this.		
Victoria Tsang	Clinical expert	Direct – Professional	Prior to the meeting, Victoria declared that her hospital employer has received fenfluramine for named patients as part of controlled access scheme for patients with Dravet syndrome from Zogenix prior to NICE guidance (TA808) being published (July 2022).	30/06/2024	It was agreed that Victoria's declaration would not prevent her from providing expert advice to the committee.
Professor Helen Cross	Clinical expert	Direct – Financial & Professional	<ul style="list-style-type: none"> Professor Cross was on Advisory Boards for Jazz, Takeda, Zogenix (UCB) and Biocodex. All remuneration went to her department. Professor Cross has been a speaker in educational symposia for UCB, Biocodex and Jazz. All remuneration went to her department. Professor Cross has been an investigator for studies sponsored by Zogenix (UCB), Jazz, Takeda, Stoke Therapeutics, Ultragenyx and 	30/06/2024 6/3/2024 15/01/2025	It was agreed that Professor Cross' declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Marinius. All remuneration went to her department.		